Search results for "Neoplasms"

showing 10 items of 7988 documents

Liquid Biopsy in Gastrointestinal Stromal Tumor

2017

Over the past 15 years, gastrointestinal stromal tumors (GISTs) have emerged from a poorly understood neoplasm to a well-defined tumor entity. Starting from 2000, the discovery of gain-of-function mutations involving KIT or PDGFRα (platelet-derived growth factor-α) genes and the development of tyrosine kinase inhibitors (TKIs), such as imatinib, revolutionized dramatically the management of GISTs. Due to the almost continual emergence of new data about biological complexity of GISTs and more sophisticated whole-genome technologies, to date, the role of molecular biology is clinically important to drive therapeutic decision making.

0301 basic medicinemedicine.medical_specialtyStromal cellbusiness.industryGeneral surgeryImatinibTherapeutic decision makingmedicine.diseasedigestive system diseases03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisCancer researchMedicineNeoplasmGastrointestinal stromal tumors (GISTs)Liquid biopsyStromal tumorbusinessneoplasmsTyrosine kinasemedicine.drug
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

ERa dimerization: a key factor for the weak estrogenic activity of an ERa modulator unable to compete with estradiol in binding assays

2016

PMID: 27400858; International audience; AbstractEstrothiazine (ESTZ) is a weak estrogen sharing structural similarities with coumestrol. ESTZ failed to compete with [3H]17β-estradiol ([3H]17β-E2) for binding to the estrogen receptor α (ERα), questioning its ability to interact with the receptor. However, detection by atomic force spectroscopy (AFS) of an ESTZ-induced ERα dimerization has eliminated any remaining doubts. The effect of the compound on the proliferation of ERα-positive and negative breast cancer cells confirmed the requirement of the receptor. The efficiency of ESTZ in MCF-7 cells was weak without any potency to modify the proliferation profile of estradiol and coumestrol. Gro…

0301 basic medicinemedicine.medical_specialtyTranscription Geneticmedicine.drug_class[SDV]Life Sciences [q-bio]ThiazinesEstrogen receptorBreast NeoplasmsPhytoestrogensCoumestrol[ CHIM ] Chemical SciencesBiochemistry[SPI.MAT]Engineering Sciences [physics]/Materials03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumans[CHIM]Chemical SciencesBinding site[SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/MicroelectronicsReceptorMolecular BiologyEstrogen receptor beta[SPI.ACOU]Engineering Sciences [physics]/Acoustics [physics.class-ph]Binding Sites[ SDV ] Life Sciences [q-bio]EstradiolSpectrophotometry AtomicEstrogen Receptor alphaCell BiologyCell biologyTranscription Factor AP-1030104 developmental biologyEndocrinologychemistryMechanism of actionEstrogen030220 oncology & carcinogenesisMCF-7 CellsFemalemedicine.symptomDimerizationEstrogen receptor alphaProtein Binding
researchProduct

Beta-glucans and cancer: The influence of inflammation and gut peptide

2017

Dietary β-glucans are soluble fibers with potentially health-promoting effects. Gut peptides are important signals in the regulation of energy and glucose homeostasis. This article reviews the effects of different enriched β-glucan food consumption on immune responses, inflammation, gut hormone and cancer. Gut hormones are influenced by enriched β-glucan food consumption and levels of such peptide as YY, ghrelin, glucagon-like peptide 1 and 2 in humans influence serum glucose concentration as well as innate and adaptive immunity. Cancer cell development is also regulated by obesity and glucose dishomeostasy that are influenced by β-glucan food consumption that in turn regulated gut hormones.

0301 basic medicinemedicine.medical_specialtybeta-GlucansInflammationbeta-Glucan03 medical and health sciences0302 clinical medicineImmune systemGlucagon-Like Peptide 1Functional FoodNeoplasmsInternal medicineβ-GlucanDrug DiscoveryGlucagon-Like Peptide 2medicineAnimalsHumansInsulinGlucose homeostasisPeptide YYCancerInflammationPharmacologyPYYAnimalChemistryDrug Discovery3003 Pharmaceutical Sciencedigestive oral and skin physiologyOrganic ChemistryGeneral MedicineGlucagon-like peptide-2Glucagon-like peptide-1GhrelinGlucose030104 developmental biologyEndocrinology030220 oncology & carcinogenesisPeptide YYNeoplasmGhrelinmedicine.symptomGLP-1GLP-2HumanHormoneEuropean Journal of Medicinal Chemistry
researchProduct

The dietary inflammatory index and human health: an umbrella review of meta-analyses of observational studies

2021

Numerous observational studies have investigated the role of the Dietary Inflammatory Index (DII®) in chronic disease risk. The aims of this umbrella review and integrated meta-analyses were to systematically synthesize the observational evidence reporting on the associations between the DII and health outcomes based on meta-analyses, and to assess the quality and strength of the evidence for each associated outcome. This umbrella review with integrated meta-analyses investigated the association between the DII and a range of health outcomes based on meta-analyses of observational data. A credibility assessment was conducted for each outcome using the following criteria: Statistical heterog…

0301 basic medicinemedicine.medical_specialtymedicinediet inflammation dietary inflammatory index prevention mental disorders cancer cardiovascular disease non-communicable disorders medicineMedicine (miscellaneous)non-communicable disordersReview03 medical and health sciences0302 clinical medicineMeta-Analysis as Topicpreventioncardiovascular diseaseInternal medicineNeoplasmsmedicineHumanscancer030212 general & internal medicineProspective cohort study030109 nutrition & dieteticsNutrition and Dieteticsbiologybusiness.industryClinical study designC-reactive proteinRandom effects modelDietmental disordersStudy heterogeneityObservational Studies as TopicSystematic reviewinflammationbiology.proteindietary inflammatory indexObservational Studies as TopicObservational studybusinessdietFood Science
researchProduct

Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease

1992

SummaryThis paper is an up-dated review of the role of systemic chemotherapy in the management of recurrent and/or metastatic head and neck carcinoma.

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyAntineoplastic AgentsDiseaseHead neck cancer03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Head and neckHead and neck carcinomaPharmacologyChemotherapybusiness.industrySystemic chemotherapyHead and neck cancerAdvanced stagemedicine.diseaseSurgeryInfectious DiseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisRadiologyNeoplasm Recurrence Localbusiness
researchProduct

Complication of endoscopic tattooing: a case report of covered perforation

2016

Aim Laparoscopy is considered a good approach in treatment of colorectal neoplastic diseases; the endoscopic tattooing is then recommended (Evidence Level III and grade of recommendation A) to mark a lesion or a polypectomy site for intraoperative identification. We describe the case of perforation after tattoing treated conservatively. Case report 63 years old woman, underwent colonoscopy for lipoma tattooing with India ink SPOT® solution kit and saline test. Immediately after the procedure the patient has been referred the appearance of colic epi-mesogastric pain and fever; Computed Tomography (CT) without MDC identified an irregular thickening of transverse colon with some microbubbles c…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentPerforation (oil well)ColonoscopyPeritonitisBacteremiaClinical Practice03 medical and health sciences0302 clinical medicineEnteral NutritionmedicineHumansLaparoscopyColoring AgentsPerforationmedicine.diagnostic_testTattooingbusiness.industryTransverse colonEndoscopyColonoscopyMiddle Agedmedicine.diseaseEndoscopy; Perforation; Surgery; Tattoing; SurgeryPolypectomyCarbonSurgeryEndoscopyAnti-Bacterial AgentsTattoing030104 developmental biologyTreatment OutcomeIntestinal Perforation030220 oncology & carcinogenesisSurgeryFemaleLipomabusinessComplicationColorectal NeoplasmsTomography X-Ray Computed
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Immunotherapeutic properties of chemotherapy

2017

IF 5.363; International audience; Impressive remissions driven by immunological checkpoint blockade in cancer patients have prompted the scientific community to investigate afresh the crosstalk between cancer cells and the patient's immune system. Preclinical and clinical studies have highlighted that the anticancer efficacy of some conventional chemotherapeutics is based on their ability to restore anticancer immune responses. The current challenge is to understand and circumvent immune resistance mechanisms to chemo- and immunotherapies to design relevant immunotherapy and chemotherapy combinations. In this review, we will summarize which immunological processes are involved in the antica…

0301 basic medicinemedicine.medical_treatmentAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesImmune systemNeoplasmsDrug DiscoveryAnimalsHumansMedicineCytotoxicityPharmacologyChemotherapybusiness.industryImmunogenicityImmunotherapyImmune checkpointGastrointestinal Microbiome3. Good healthBlockade030104 developmental biologyImmunologyCancer cellCancer researchImmunotherapybusinessCurrent Opinion in Pharmacology
researchProduct

Personalized vaccines for cancer immunotherapy

2018

Cancer is characterized by an accumulation of genetic alterations. Somatic mutations can generate cancer-specific neoepitopes that are recognized by autologous T cells as foreign and constitute ideal cancer vaccine targets. Every tumor has its own unique composition of mutations, with only a small fraction shared between patients. Technological advances in genomics, data science, and cancer immunotherapy now enable the rapid mapping of the mutations within a genome, rational selection of vaccine targets, and on-demand production of a therapy customized to a patient’s individual tumor. First-in-human clinical trials of personalized cancer vaccines have shown the feasibility, safety, and immu…

0301 basic medicinemedicine.medical_treatmentBioinformaticsmedicine.disease_causeCancer Vaccines03 medical and health sciences0302 clinical medicineCancer immunotherapyAntigens NeoplasmNeoplasmsmedicineHumansPrecision MedicineMutationMultidisciplinaryImmunodominant EpitopesCancerImmunotherapyPrecision medicinemedicine.diseaseVaccinationClinical trial030104 developmental biology030220 oncology & carcinogenesisMutationImmunotherapyCancer vaccineScience
researchProduct